New combo attack on hard-to-treat lymphoma shows promise in early trial
Disease control
Recruiting now
This study tests whether adding two antibody drugs (mosunetuzumab and polatuzumab) after standard CAR-T cell therapy can improve tumor shrinkage in people with aggressive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. About 22 adults will receive the…
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC